Approval · Notice of Compliance 6280 · 2005
STREPTASE: Notice of Compliance 6280
Issued February 16, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6280
- Date
- February 16, 2005
- Company
- Zlb Behring GmbhKing Of Prussia, Pennsylvania, United States
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Fibrinolytic agent
Products in this notice
Medicinal ingredients
- STREPTOKINASE 250,000 UNIT per VIAL
- STREPTOKINASE 750,000 UNIT per VIAL
- STREPTOKINASE 1,500,000 UNIT per VIAL